Aridis Pharmaceuticals Stock News

Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.

Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer signif

Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.

Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Aridis Pharmaceuticals (ARDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreeme

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of 13.73% and 40.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aridis Pharmaceuticals Inc''s (NASDAQ: ARDS ) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant . Both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration. Both mAbs in the AR-701 cocktail, i.e., AR-720 and AR-703, … Full story available on Benzinga.com

Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. 10x Genomics (TXG) -16%. iSpecimen ISPC -10%.

As far as short squeeze stocks go, these five companies top the list in terms of both short interest and borrow fee rates right now. The post Short Squeeze Stocks: ARDS, BBIG and 3 Others Experts Thin

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Are these short squeeze penny stocks on our watch list right now? The post 4 Short Squeeze Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information

Aridis Pharmaceuticals ARDS +27%. Galapagos GLPG +16%. Immix Biopharma IMMX +15%. Epizyme (EPZM) -34%. Cue Biopharma (CUE) -16%.

The Bill & Melinda Gates Foundation has granted $1.9 million to Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) to evaluate Aridis'' inhaled monoclonal antibodies (mAbs) against influenza and COVID-19 for low- and middle-income countries. The mAbs will be manufactured using a spirulina-based platform technology developed by Lumen Bioscience. Lumen Bio''s platform can produce therapeutic proteins at lower costs than conventional Full story available on Benzinga.com